CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 9, 2008--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines primarily for cancer treatment, today announced that it will be presenting data from its pipeline of oncology programs at the upcoming American Association for Cancer Research (AACR) Annual Meeting being held in San Diego, CA, April 12-16.
Curis scientists will be discussing two posters that highlight preclinical data from the company's compounds, CUDC-101 and CU-0201, both small molecule, multi-target inhibitors generated by Curis' proprietary targeted cancer drug development platform.
Sunday, Apr 13, 2008, 8:00 AM -12:00 PM
Location: Exhibit Hall B-F, San Diego Convention Center
Session: Histone Deacetylase Inhibitors and Cell Cycle Inhibitors
Presentation Title: Anti-tumor activity of CUDC-101, a novel small molecule inhibitor of HDAC, EGFR and Her2, in hepatocellular cancer (HCC)
Poster Section/Board Number: 32/10
Abstract Number: 737
Wednesday, Apr 16, 2008, 8:00 AM -12:00 PM
Location: Exhibit Hall B-F, San Diego Convention Center
Session: Novel Small Molecule Cancer Therapeutics 2
Presentation Title: CU-0201, a potent, small molecule, multi-targeted inhibitor of HDAC, Abl and Src, effectively inhibits proliferation of both hematological and solid-tumor derived cancer cell lines
Poster Section/Board Number: 31/30
Abstract Number: 5717
In addition, there will be several presentations related to the Hedgehog Antagonist Program, in collaboration with Genentech, including a late-breaking presentation on Phase I data for GDC-0449, a small molecule Hedgehog antagonist.
Saturday, Apr 12, 2008, 3:15 PM - 3:40 PM
Location: Room 30A-C, San Diego Convention Center
Session Title: Emerging Targets: Wnt, Notch, Sonic Hedgehog
Presentation Title: Hedgehog: From bench to clinic
Sunday, Apr 13, 2008, 2:20 PM
Location: Ballroom 20A-C, San Diego Convention Center
Session Title: New Drugs on the Horizon 1
Presentation Title: Small molecule antagonists of the hedgehog pathway
Monday, Apr 14, 2008, 9:15 AM - 9:35 AM
Location: Hall G-H, San Diego Convention Center
Session: Clinical Plenary Session 1: Breakthroughs in Phase I, II, and III Clinical Trials
Presentation Title: Efficacy data of GDC-0449, a systemic Hedgehog pathway antagonist, in a first-in-human, first-in-class Phase I study with locally advanced, multifocal or metastatic basal cell carcinoma patients
Abstract Number: LB-138
Tuesday, Apr 15, 2008, 8:00 AM -12:00 PM
Location: Exhibit Hall B-F, San Diego Convention Center
Session Title: Novel Assays and Technologies
Presentation Title: Development of a clinical hedgehog antagonist qRT-PCR pharmacodynamic assay for Gli1 in hair follicle samples
Poster Section/Board Number: 11/15
Abstract Number: 3656
Tuesday, Apr 15, 2008, 1:00 PM - 5:00 PM
Location: Exhibit Hall B-F, San Diego Convention Center
Session Title: Stem Cells in the Gastrointestinal and Genitourinary Tracts
Presentation Title: Autocrine hedgehog signaling is not involved in pancreatic ductal adenocarcinoma initiation and progression
Poster Section/Board Number: 15/9
Abstract Number: 4583
Wednesday, Apr 16, 2008, 8:00 AM -12:00 PM
Location: Exhibit Hall B-F, San Diego Convention Center
Session Title: Stem Cells
Presentation Title: A paracrine requirement for Hedgehog signaling in cancer
Poster Section/Board Number: 15/26
Abstract Number: 5431
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new medicines, primarily for cancer. In expanding its drug development efforts in the field of cancer through its targeted cancer drug development platform, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.
CONTACT: Curis, Inc.
Michael P. Gray, 617-503-6632
Chief Financial Officer
mgray@curis.com
SOURCE: Curis, Inc.